Erlocip also known as Erlotinib is a prescription drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It interfers with the protein epidermal growth factor, preventing it from activating enzymes which is required in certain cancer cells to grow and multiply.
Manufacturer : Cipla Ltd.
Strengths available : 100mg & 150mg
Storage : Store in a cool dry place
Dosage : ERLOCIP Tablets treatment should be supervised by a physician experienced in the use of anti-cancer therapies.
Recommended Dose: NSCLC
EGFR mutation testing should be performed prior to initiation of ERLOCIP Tablets therapy in chemo-naïve patients with advanced or metastatic NSCLC.
The recommended daily dose of ERLOCIP Tablets for NSCLC is 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs. There is no evidence that treatment beyond progression is beneficial.
Recommended Dose: Pancreatic Cancer
The recommended daily dose of ERLOCIP Tablets for pancreatic cancer is 100 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food, in combination with gemcitabine. Treatment should continue until disease progression or unacceptable toxicity occurs.
In patients who do not develop rash within the first 4–8 weeks of treatment, further treatment with ERLOCIP Tablets should be re-assessed.
When dose adjustment is necessary, the dose should be reduced in steps of 50 mg. Concomitant use of CYP3A4 substrates and modulators may require dose adjustment.
Most common side effects are Nausea, Vomiting, Fatigue, Breathing difficulty, Abdominal pain, Edema, Weight loss, Loss of appetite, Anemia, Infection, Bone pain, Constipation, Diarrhea, Fever, Stomatitis (Inflammation of the mouth), Rash.